Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Breaking & Recent News Aditxt Inc ADTX

Healthcare Biotechnology
Aditxt, Inc., a commercial-stage company, discovers and develops products in the areas of immune health, precision health, population health, women’s health, and neurologic health. The company develops AditxtScore that enable individuals to understand, manage, and monitor their immune profiles in order to be informed about attacks on or by their immune system; and Apoptotic DNA Immunotherapy, a... see more

Recent & Breaking News (NDAQ:ADTX)

Aditxt Provides Updates on its Growth Vision for bitXbio(TM), Planned Digital Asset Treasury, Pearsanta's Planned IPO, And Evofem's Plan to Regain a National Listing

Business Wire November 18, 2025

Aditxt, Inc. (NASDAQ: ADTX) Announces 1-for-113 Reverse Stock Split Effective at the Open of Trading on November 3, 2025

Business Wire October 29, 2025

Aditxt Subsidiary Pearsanta Begins Enrollment in First Human Study of Blood-Based Diagnostic for Endometriosis, a Condition Affecting 190 Million Women Worldwide and Representing a $1.45 Billion Global Market

Business Wire October 27, 2025

Evofem Announces Voting Results from Special Meeting of Stockholders

PR Newswire October 20, 2025

Evofem's "Say Vagina" Campaign Generates More than 2.5 Million Views Across Social Media Platforms

PR Newswire September 11, 2025

Evofem Anticipates Approval of Merger with Aditxt at Upcoming Stockholder Meeting

PR Newswire September 9, 2025

Aditxt's Subsidiary Adimune Highlights Its Approach to Reprogramming the Immune System Through DNA Instructions, Now with 96 Granted and 22 Pending Patents Targeting Autoimmunity Market Estimated at Over $160 Billion by 2030

Business Wire August 25, 2025

Illinois Pharmacists Can Prescribe PHEXXI Starting January 2026 Under Newly-passed Law

PR Newswire August 21, 2025

Aditxt and Crypto.com Sign Agreement for Custodial Crypto Account, Announce ADTX Share Access on Crypto.com as Part of the Larger bitXbio(TM) Initiative

Business Wire August 11, 2025

Evofem CEO Saundra Pelletier Honored with Trailblazing Female Founders Award at STIMULATE Conference

PR Newswire August 5, 2025

Aditxt's Subsidiary, Pearsanta, Inc. Engages Spartan Capital as Lead Underwriter for its Planned IPO Intending to Drive Clinical Validation and Commercial Rollout of Its Mitomic(TM) Platform Technology for Early Detection of Cancers and Other Diseases

Business Wire July 29, 2025

Aditxt's Subsidiary Pearsanta Receives an Invitation to Submit Full Proposal for the U.S. Department of Defense Pilot Award for the Development of its Mitomic® Ovarian Test

Business Wire July 24, 2025

Aditxt to Present at Wall Street Reporter's Next Super Stock Livestream Today July 22, 2025, at 1 p.m. ET

Business Wire July 22, 2025

Phexxi -- A Non‑Hormonal Birth Control Brand -- Goes Viral with Microfeminism on TikTok, Featured by BuzzFeed and Scary Mommy

PR Newswire July 15, 2025

Aditxt Unveils bitXbio(TM): A Bitcoin-Backed Treasury Strategy Designed to Accelerate Biotech Commercialization

Business Wire July 7, 2025

Aditxt to Present at Wall Street Reporter's NEXT SUPER STOCK Livestream Today June 26, 2025, at 1 p.m. ET

Business Wire June 26, 2025

Evofem Biosciences' CEO Saundra Pelletier Joins Aditxt Board of Directors

Business Wire June 9, 2025

Saundra Pelletier, Evofem Biosciences' CEO, Dr. Friedrich Kapp, Co-CEO of Adimune, and Chris Mitton, President of Pearsanta, Will Join Aditxt Weekly Update on June 6

Business Wire June 5, 2025

Appili Therapeutics Provides Update on Arrangement with Aditxt, Inc.

GlobeNewswire May 19, 2025

Aditxt Announces Termination of Arrangement Agreement With Appili Therapeutics

Business Wire May 19, 2025